Mitchel J R Ruigrok (Mitchel Jr Ruigrok)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

High Resolution

Inflammatory Response

Replacement Therapy

Top Venues

Expert opinion on drug delivery

This page only lists publications with an associated author ORCID identifier.

Publications

Kurnia S S Putri, Adhyatmika Adhyatmika, Carian E Boorsma, Habibie Habibie, Mitchel J R Ruigrok, Peter Heukels, Hidde J Haisma, Marina H de Jager, Wouter L J Hinrichs, Peter Olinga, Barbro N Melgert
Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis. Lung (2024)
Kurnia S S Putri, Adhyatmika Adhyatmika, Carian E Boorsma, Habibie Habibie, Mitchel J R Ruigrok, Peter Heukels, Hidde J Haisma, Marina H de Jager, Wouter L J Hinrichs, Peter Olinga, Barbro N Melgert
Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis. Lung 202 (3) (2024)
Kurnia S S Putri, Adhyatmika Adhyatmika, Carian E Boorsma, Habibie Habibie, Mitchel J R Ruigrok, Peter Heukels, Hidde J Haisma, Marina H de Jager, Wouter L J Hinrichs, Peter Olinga, Barbro N Melgert
Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis. Lung 202 (3) (2024)
Kurnia S S Putri, Adhyatmika Adhyatmika, Carian E Boorsma, Habibie Habibie, Mitchel J R Ruigrok, Peter Heukels, Hidde J Haisma, Marina H de Jager, Wouter L J Hinrichs, Peter Olinga, Barbro N Melgert
Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis. Lung 202 (3) (2024)
Evalyne M Jansen, Henderik W Frijlink, Wouter L J Hinrichs, Mitchel J R Ruigrok
Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. Expert opinion on drug delivery 19 (11) (2022)